Загрузка...
Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...
Сохранить в:
| Опубликовано в: : | Circ Rep |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
The Japanese Circulation Society
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7819654/ https://ncbi.nlm.nih.gov/pubmed/33693263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0062 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|